Highly potent visnagin derivatives inhibit Cyp1 and prevent doxorubicin cardiotoxicity-Reference-Cited by-同舟云学术

Highly potent visnagin derivatives inhibit Cyp1 and prevent doxorubicin cardiotoxicity

Published:2018-01-11 Issue:1 Volume:3 Page:
ISSN:2379-3708
Container-title:JCI Insight
language:en
Short-container-title:

Author:

Asnani Aarti,Zheng Bahoui,Liu Yan,Wang You,Chen Howard H.,Vohra Anita,Chi An,Cornella-Taracido Ivan,Wang Huijun,Johns Douglas G.,Sosnovik David E.,Peterson Randall T.

Funder

Merck

American Heart Association

Harvard Medical School

Publisher

American Society for Clinical Investigation

Subject

General Medicine

Link

https://insight.jci.org/articles/view/96753/files/pdf

Reference38 articles.

1. The CO/HO system reverses inhibition of mitochondrial biogenesis and prevents murine doxorubicin cardiomyopathy

2. Doxorubicin-Induced Cardiac Mitochondrionopathy

3. Cumulative and irreversible cardiac mitochondrial dysfunction induced by doxorubicin;Zhou;Cancer Res,2001

4. Dexrazoxane: how it works in cardiac and tumor cells. Is it a prodrug or is it a drug?

5. Cardiotoxicity of doxorubicin is mediated through mitochondrial iron accumulation

Cited by 37 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. TnP and AHR-CYP1A1 Signaling Crosstalk in an Injury-Induced Zebrafish Inflammation Model;Pharmaceuticals;2024-08-31

2. Therapeutic potential and pharmacological mechanism of visnagin;Journal of Integrative Medicine;2024-07

3. Visnagin: A novel cardioprotective agent against anthracycline toxicity (Review);Medicine International;2024-05-13

4. Inhibition of Cyp1a Protects Mice against Anthracycline Cardiomyopathy;2024-04-11

5. Toxic effects of cancer therapies;Public Health and Toxicology Issues Drug Research, Volume 2;2024